Sandoz will pay $450 million to settle generic price-fixing claims and says its outlook is unchanged.
The deal carries no admission. The company had already reserved for it.
Sandoz and its Fougera unit agreed on August 3, 2026, to settle with 43 states and territories over alleged price-fixing and market allocation in generic drugs. They will pay $400 million over seven years from 2027, plus about $50 million to states that settled earlier. A further $28.5 million would settle with indirect resellers.
This is not the first payment. Sandoz's former parent, Novartis, paid $195 million in 2020 to resolve a federal criminal claim and $185 million on the civil side. Sandoz paid $265 million to purchaser classes in 2024.
Sandoz says none of it affects 2026 guidance or its mid-term outlook. That is the point. More than $1 billion across four resolutions has been absorbed as a cost of doing business, with the payments spread out to 2033.
The people who overpaid were patients and Medicaid programs buying everyday generics. They are being repaid slowly, by a company that concedes nothing.
Sources
- pharmexec.com · pharmexec.com/view/sandoz-agrees-450-million-settlement-43-us-states-over-generic-drug-ant…
- pharmaphorum.com · pharmaphorum.com/news/sandoz-will-pay-another-480m-settle-us-antitrust-suits
Cite this report
The Precedent. "Sandoz will pay $450 million to settle generic price-fixing claims and says its outlook is unchanged.." September 12, 2026. https://theprecedent.org/article/sandoz-will-pay-450-million-to-settle-generic-price-fixing-claims-and-says-its-o
